Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers

Kunal N. Karmali, Ji Young Lee, Tiffany Brown, Stephen D. Persell*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Although cholesterol guidelines emphasize cardiovascular disease (CVD) risk to guide primary prevention, predictors of statin use in practice are unknown. We aimed to identify factors associated with a cholesterol treatment discussion and statin prescribing in a high-risk population. Methods: We used data from a trial conducted among participants in community health centers without CVD or diabetes and a 10-year coronary heart disease (CHD) risk ≥ 10%. Cholesterol treatment discussion was assessed at 6 months and statin prescription at 1 year. We used logistic regressions to identify factors associated with each outcome. Results: We analyzed 646 participants (89% male, mean age 60 ± 9.5 years). Cholesterol treatment discussion occurred in 19% and statin prescription in 12% of participants. Ten-year CHD risk was not associated with treatment discussion (OR 1.11 per 1 SD increase, 95% CI 0.91-1.33) but was associated with statin prescription (OR 1.41 per 1 SD increase, 95% CI 1.13-1.75) in unadjusted models. After adjusting for traditional CVD risk factors that contribute to CHD risk, low-density lipoprotein cholesterol (LDL-C) was independently associated with statin prescription (OR 1.82 per 1 SD increase, 95% CI 1.66-1.99). Antihypertensive medication use was independently associated with both cholesterol treatment discussion (OR 3.68, 95% CI 2.35-5.75) and statin prescription (OR 3.98, 95% CI 3.30-4.81). Other drivers of CVD risk (age, smoking, and systolic blood pressure) were not associated with statin use. Conclusions: Single risk factor management strongly influences cholesterol treatment discussions and statin prescribing patterns. Interventions that promote risk-based statin utilization are needed. Trial registration: Clinicaltrials.gov.: NCT01610609.

Original languageEnglish (US)
Pages (from-to)176-181
Number of pages6
JournalPreventive medicine
Volume88
DOIs
StatePublished - Jul 1 2016

Keywords

  • Cardiovascular disease prevention
  • Cholesterol
  • Risk assessment

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers'. Together they form a unique fingerprint.

Cite this